Our oncology pipeline holds promise in the near term through our later-stage priority programs, and our early pipeline includes several potentially groundbreaking modalities. All are selective, clearly differentiated and have the potential to be best-in-class. 

We focus on four innovation clusters:

• Oncogenic Signaling
• DNA Damage Response (DDR)
• Antibody-Drug Conjugates (ADCs)
• Tumor Immunology

As part of our commitment to precision medicine, we use predictive biomarkers to identify those patient populations that are most likely to respond to treatment. Moreover, we apply pharmacodynamic biomarkers in order to guide optimal dosing and thereby increase the probability of success in clinical development.

We believe that rational combinations are key to developing new treatment options. Therefore, we are currently combining selected targeted therapies with chemotherapy, radiation therapy, other targeted agents and/or immunotherapies, leveraging our own as well as external portfolios and partnerships to identify new ways to possibly improve patient outcomes.

We are aware that we can identify and develop therapies and biomarkers for patients better and faster with the help of external collaborations. We collaborate with leading academic institutions and industry innovators to complement our pipeline, strengthen our technology base and enhance our scientific capabilities.

View our pipeline to see what we’re currently working on across therapeutic areas and clinical development phases. Learn more